<p>Homologous recombination repair (HRR) gene alterations in prostate cancer predispose patients to more aggressive disease and a poorer prognosis. The presence of these HRR gene alterations may inform patient eligibility for clinical trials and targeted therapies, and importantly, through cascade testing, help identify family members at risk of developing an inherited cancer. This finding highlights the importance of testing for HRR gene alterations in patients with prostate cancer. Despite the potential implications of such testing to patient care, in a cross-sectional retrospective study in the USA, only 37.7% of patients with advanced prostate cancer underwent HRR testing between 2014 and 2022. The aim of this podcast is to identify obstacles to testing for HRR gene alterations that healthcare professionals encounter in day-to-day clinical practice, as well as discuss ways to potentially overcome them. In this multidisciplinary podcast, a genetic counselor, a medical oncologist, and a urologist discuss the importance of testing for HRR gene alterations and, using their different clinical perspectives, explore ways that healthcare professionals can integrate testing results into clinical practice.</p>